addgene addgene plasmid Search Results


93
Addgene inc 1 ap
1 Ap, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pm41850230-452-37-61?v=Addgene+inc
Average 93 stars, based on 1 article reviews
1 ap - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Addgene inc plv teto hngn2 egfp puro
Plv Teto Hngn2 Egfp Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pm36997626-347-18-19?v=Addgene+inc
Average 94 stars, based on 1 article reviews
plv teto hngn2 egfp puro - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
Addgene inc pcmv ancbe4max
Pcmv Ancbe4max, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pmc07145270-116-4-5?v=Addgene+inc
Average 93 stars, based on 1 article reviews
pcmv ancbe4max - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

92
Addgene inc gfp rab7a
Gfp Rab7a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pmc11399591-270-0-7?v=Addgene+inc
Average 92 stars, based on 1 article reviews
gfp rab7a - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

93
Addgene inc gw1
Gw1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/10__1091_slash_mbc__e17___01___0041-134-10-11?v=Addgene+inc
Average 93 stars, based on 1 article reviews
gw1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Addgene inc ej2
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Ej2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pmc12661054-306-7-8?v=Addgene+inc
Average 93 stars, based on 1 article reviews
ej2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Addgene inc human ubch5c e2
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Human Ubch5c E2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pmc07644731-395-17-21?v=Addgene+inc
Average 93 stars, based on 1 article reviews
human ubch5c e2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Addgene inc tom20 mcherry fkbp addgene
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Tom20 Mcherry Fkbp Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pm40925364-274-151-152?v=Addgene+inc
Average 93 stars, based on 1 article reviews
tom20 mcherry fkbp addgene - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

92
Addgene inc pskduet01
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Pskduet01, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pm38864750-193-2-3?v=Addgene+inc
Average 92 stars, based on 1 article reviews
pskduet01 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

92
Addgene inc pmruby2 lamina
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Pmruby2 Lamina, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pmc09206027-211-38-39?v=Addgene+inc
Average 92 stars, based on 1 article reviews
pmruby2 lamina - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

92
Addgene inc pgv15 ck2α k68m
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Pgv15 Ck2α K68m, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/bio_rxiv__2023__12__10__570918-61-8-14?v=Addgene+inc
Average 92 stars, based on 1 article reviews
pgv15 ck2α k68m - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

96
Addgene inc hairpin to tp53
a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in <t>EJ2</t> reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.
Hairpin To Tp53, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/addgene+addgene+plasmid/pm27345789-29-22-26?v=Addgene+inc
Average 96 stars, based on 1 article reviews
hairpin to tp53 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

Image Search Results


a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in EJ2 reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.

Journal: Nature Communications

Article Title: The CIP2A-TOPBP1 axis facilitates mitotic DNA repair via MiDAS and MMEJ

doi: 10.1038/s41467-025-65594-2

Figure Lengend Snippet: a Representative images and dot plot showing the number of TOPBP1–MUS81 colocalising foci in RPE1 p53 -/- FRT/TR WT or CIP2A -/- prometaphase cells following 400 nM aphidicolin for 18 h and synchronisation with 60 ng/ml nocodazole for 2 h (WT: n = 78; CIP2A -/- Cl.1: n = 79; Cl.2: n = 80; three independent experiments). b Representative images and dot plot of EdU foci in prometaphase RPE1 p53 -/- WT or CIP2A -/- cells after following 400 nM aphidicolin followed by 30 min synchronisation with 60 ng/ml nocodazole (WT: n = 77; Cl.1: n = 69; Cl.2: n = 74; three experiments). c EdU foci in prometaphase DLD1 BRCA2 -/- cells treated with siCTRL or siCIP2A (siCTRL: n = 75; siCIP2A: n = 74; three experiments; significance determined by two-tailed unpaired t-test). d Bar plot showing break-induced replication (BIR) efficiency after sgRNP-CAS9 cleavage of an I-SceI site in the pBIR-GFP reporter U2OS cell line treated with siCTRL, siPOLD3, siCIP2A, or siSLX4 (four experiments). e Representative images and dot plot of CIP2A–γH2AX colocalising foci in RPE1 p53 -/- FRT/TR WT cells untreated or treated with 400 nM aphidicolin for 18 h followed by synchronisation with 60 ng/ml nocodazole for 2 h (UT: n = 82; Aph: n = 69; three experiments; two-tailed unpaired t-test). f Representative images and dot plot of FANCD2–CIP2A colocalising foci in RPE1 p53 -/- WT cells under the same conditions as ( e ) (UT: n = 75; Aph: n = 70; three experiments; two-tailed unpaired t-test). g eGFP-Polθ foci in prometaphase DLD1 BRCA2 -/- eGFP-Polθ cells treated with doxycycline (100 ng/ml, 24 h) 48 h after siRNA treatment with siCTRL or siCIP2A for (siCTRL: n = 86; siCIP2A: n = 83; three experiments; two-tailed unpaired t-test). h Bar plot of alternative end-joining (Alt-EJ)/microhomology-mediated end joining (MMEJ) efficiency after sgRNP-Cas9 cleavage of an I-SceI site in EJ2 reporter U2OS cells treated with siCTRL, siPolθ, or siCIP2A (three experiments). In ( a , b , c , e , f , g ), grey dots represent individual measurements, black dots indicate medians per experiment, and bars show mean ± SEM. Scale bars: 10 µm. Statistical significance: a, b, d, and h by one-way ANOVA; others by two-tailed unpaired t-test. Source data are provided as a file.

Article Snippet: U2OS cells (RRID: CVCL_0042) stably integrated with EJ2 (RRID:Addgene_44025 ), a gift from J. M. Stark and pBIR (RRID:Addgene_49807 ), a gift from T. D. Halazonetis, were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum (FBS).

Techniques: Two Tailed Test